In a clinical study of sarcopenic COPD patients, Bimagrumab (an ACVR2 inhibitor that blocks the myostatin pathway) was found to safely increase skeletal muscle mass in patients with COPD, but no improvement in muscle function or physical performance was observed (87). The gene discussed is ACVR2A; the disease is chronic obstructive pulmonary disease.